273 related articles for article (PubMed ID: 19706371)
1. Role of 14-3-3 protein and oxidative stress in diabetic cardiomyopathy.
Watanabe K; Thandavarayan RA; Gurusamy N; Zhang S; Muslin AJ; Suzuki K; Tachikawa H; Kodama M; Aizawa Y
Acta Physiol Hung; 2009 Sep; 96(3):277-87. PubMed ID: 19706371
[TBL] [Abstract][Full Text] [Related]
2. Glycogen synthase kinase 3beta together with 14-3-3 protein regulates diabetic cardiomyopathy: effect of losartan and tempol.
Gurusamy N; Watanabe K; Ma M; Prakash P; Hirabayashi K; Zhang S; Muslin AJ; Kodama M; Aizawa Y
FEBS Lett; 2006 Apr; 580(8):1932-40. PubMed ID: 16530186
[TBL] [Abstract][Full Text] [Related]
3. Oxidative stress: a key contributor to diabetic cardiomyopathy.
Khullar M; Al-Shudiefat AA; Ludke A; Binepal G; Singal PK
Can J Physiol Pharmacol; 2010 Mar; 88(3):233-40. PubMed ID: 20393588
[TBL] [Abstract][Full Text] [Related]
4. Role of differential signaling pathways and oxidative stress in diabetic cardiomyopathy.
Watanabe K; Thandavarayan RA; Harima M; Sari FR; Gurusamy N; Veeraveedu PT; Mito S; Arozal W; Sukumaran V; Laksmanan AP; Soetikno V; Kodama M; Aizawa Y
Curr Cardiol Rev; 2010 Nov; 6(4):280-90. PubMed ID: 22043204
[TBL] [Abstract][Full Text] [Related]
5. 14-3-3 protein regulates Ask1 signaling and protects against diabetic cardiomyopathy.
Thandavarayan RA; Watanabe K; Ma M; Veeraveedu PT; Gurusamy N; Palaniyandi SS; Zhang S; Muslin AJ; Kodama M; Aizawa Y
Biochem Pharmacol; 2008 May; 75(9):1797-806. PubMed ID: 18342293
[TBL] [Abstract][Full Text] [Related]
6. Interplay between impaired calcium regulation and insulin signaling abnormalities in diabetic cardiomyopathy.
Lebeche D; Davidoff AJ; Hajjar RJ
Nat Clin Pract Cardiovasc Med; 2008 Nov; 5(11):715-24. PubMed ID: 18813212
[TBL] [Abstract][Full Text] [Related]
7. Oxidative stress and diabetic cardiomyopathy: a brief review.
Cai L; Kang YJ
Cardiovasc Toxicol; 2001; 1(3):181-93. PubMed ID: 12213971
[TBL] [Abstract][Full Text] [Related]
8. Metallothionein suppresses angiotensin II-induced nicotinamide adenine dinucleotide phosphate oxidase activation, nitrosative stress, apoptosis, and pathological remodeling in the diabetic heart.
Zhou G; Li X; Hein DW; Xiang X; Marshall JP; Prabhu SD; Cai L
J Am Coll Cardiol; 2008 Aug; 52(8):655-66. PubMed ID: 18702970
[TBL] [Abstract][Full Text] [Related]
9. Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways.
Huynh K; Bernardo BC; McMullen JR; Ritchie RH
Pharmacol Ther; 2014 Jun; 142(3):375-415. PubMed ID: 24462787
[TBL] [Abstract][Full Text] [Related]
10. Diabetic cardiomyopathy and oxidative stress: role of antioxidants.
Thandavarayan RA; Giridharan VV; Watanabe K; Konishi T
Cardiovasc Hematol Agents Med Chem; 2011 Oct; 9(4):225-30. PubMed ID: 21902660
[TBL] [Abstract][Full Text] [Related]
11. Evidence for a causal role of oxidative stress in the myocardial complications of insulin resistance.
Ritchie RH
Heart Lung Circ; 2009 Feb; 18(1):11-8. PubMed ID: 19119069
[No Abstract] [Full Text] [Related]
12. Oxidative stress and stress signaling: menace of diabetic cardiomyopathy.
Wold LE; Ceylan-Isik AF; Ren J
Acta Pharmacol Sin; 2005 Aug; 26(8):908-17. PubMed ID: 16038622
[TBL] [Abstract][Full Text] [Related]
13. Deficiency of senescence marker protein 30 exacerbates angiotensin II-induced cardiac remodelling.
Misaka T; Suzuki S; Miyata M; Kobayashi A; Shishido T; Ishigami A; Saitoh S; Hirose M; Kubota I; Takeishi Y
Cardiovasc Res; 2013 Aug; 99(3):461-70. PubMed ID: 23723062
[TBL] [Abstract][Full Text] [Related]
14. The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy.
Asbun J; Villarreal FJ
J Am Coll Cardiol; 2006 Feb; 47(4):693-700. PubMed ID: 16487830
[TBL] [Abstract][Full Text] [Related]
15. Attenuation by metallothionein of early cardiac cell death via suppression of mitochondrial oxidative stress results in a prevention of diabetic cardiomyopathy.
Cai L; Wang Y; Zhou G; Chen T; Song Y; Li X; Kang YJ
J Am Coll Cardiol; 2006 Oct; 48(8):1688-97. PubMed ID: 17045908
[TBL] [Abstract][Full Text] [Related]
16. [Diabetic cardiomyopathy].
Huang YQ; Wang X; Kong W
Sheng Li Ke Xue Jin Zhan; 2010 Feb; 41(1):31-6. PubMed ID: 21417012
[TBL] [Abstract][Full Text] [Related]
17. Phospholipid-mediated signaling systems as novel targets for treatment of heart disease.
Tappia PS
Can J Physiol Pharmacol; 2007 Jan; 85(1):25-41. PubMed ID: 17487243
[TBL] [Abstract][Full Text] [Related]
18. An overview of the crosstalk between inflammatory processes and metabolic dysregulation during diabetic cardiomyopathy.
Palomer X; Salvadó L; Barroso E; Vázquez-Carrera M
Int J Cardiol; 2013 Oct; 168(4):3160-72. PubMed ID: 23932046
[TBL] [Abstract][Full Text] [Related]
19. Glycolaldehyde induces oxidative stress in the heart: a clue to diabetic cardiomyopathy?
Lorenzi R; Andrades ME; Bortolin RC; Nagai R; Dal-Pizzol F; Moreira JC
Cardiovasc Toxicol; 2010 Dec; 10(4):244-9. PubMed ID: 20632216
[TBL] [Abstract][Full Text] [Related]
20. Taxifolin prevents diabetic cardiomyopathy in vivo and in vitro by inhibition of oxidative stress and cell apoptosis.
Sun X; Chen RC; Yang ZH; Sun GB; Wang M; Ma XJ; Yang LJ; Sun XB
Food Chem Toxicol; 2014 Jan; 63():221-32. PubMed ID: 24269735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
